Eltanexor Z-isomer (KPT-8602 Z-isomer) is primarily investigated for its potential in cancer therapy, particularly in targeting hematologic malignancies. It functions as a selective inhibitor of nuclear export (SINE), specifically inhibiting the exportin protein XPO1. This mechanism leads to the accumulation of tumor suppressor proteins and cell cycle regulators within the nucleus, inducing cancer cell apoptosis. Its application is being explored in preclinical and clinical studies for treating conditions such as multiple myeloma, acute myeloid leukemia, and other solid tumors. The Z-isomer is of interest due to its potential for improved efficacy and reduced toxicity compared to other isomers, making it a promising candidate for targeted cancer treatments.